213
phase 2 trial. Lancet 2015;385:1075-86.
37.
Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A
et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection
with hepatitis C virus genotype 1 in non-responders to pegylated interferon and
ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet
2014; 384:1756–1765.
38.
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski
MS et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment
options. N Engl J Med 2013;368:1867-1877.
39.
Asselah T. Optimism for patients with genotype 4 HCV infection: clinical trials with
direct acting antivirals finally available. J Hepatol 2015; 62: 996-9.
Kronik HCV Enfeksiyonunda Yeni İlaçlar
